Key Takeaways
- Resilient quarter, cautious outlook: Revenue and profitability grew 8% and 11% respectively in a weak chemical sector, but management sees a full market turnaround as six to nine months away and calls the old EBITDA target a "tough call."
- Diversification is working as designed: Glass-lined has fallen from 80–90% of the business to 50%, and chemicals/pharma from 80–90% to 50%; non-glass-lined and system platforms drove a 14% order intake jump, cushioning the core portfolio's weakness.
- Indian glass-line orders doubled sequentially: Order intake surged from the 70–90 crore range to 150–160 crores in Q4, suggesting market-share gains even as end-market demand stays sluggish.
- International margins are stable but not expanding: Restructuring in Europe and a slow China are offsetting recovery signals in the Americas; management expects international margins to trade around current levels for FY25.
- What to watch next quarter: Whether the Indian glass-line order momentum holds, the pace of pharma and chemical recovery, and the new three-year guidance promised at the upcoming Investor Day.
Demand & Order Intake
- Indian glass-line rebound: Order intake in the last two quarters doubled to 150–160 crores from the 70–90 crore range earlier in the year, driven partly by market-share gains in a slow market where the company competes vigorously on manufacturing efficiency.
- International intake lagging revenue: International order intake is lower than last year's revenue because decision-making has been slower than usual, though the pipeline remains strong and positivity is visible in the US and Europe.
- Pharma leading the recovery: Pharma is already seeing a nice recovery with large investments coming and contract manufacturing picking up; this vertical looks good for the future.
- Chemicals and agrochemicals still overstocked: The overstocking problem is expected to reduce in the next couple of quarters, but a significant change is about nine months away; the next couple of quarters will look similar with only marginal improvement.
- Replacement cycle tailwind building: Reactors supplied to Indian chemical companies over the last 10–12 years are now aging (typical life 7–9 years), and management expects this installed base to start generating reglass and service revenue.
Tarak Patel: "But generally, in terms of environment, if you had to compare with 12-months ago, I would still say that we are probably looking at slightly a more positive outlook. However, are we out of the woods yet? I would say we still have maybe six or nine months before we see a complete turnaround."
Diversification & Portfolio Shift
- Deliberate strategy paying off: Management has deliberately reduced glass-lined from 80–90% of the business to 50%, and chemicals/pharma from 80–90% to 50%; when glass-lined slowed, the other businesses performed well and helped maintain margins.
- Non-glass-lined driving order growth: Q4 order intake grew 14% to about Rs. 861 crores, driven by non-glass-lined technologies and system platforms, a direct result of the diversification push.
- Heavy engineering entering new markets: The heavy engineering business has catered to the Adani group and Reliance, markets completely different from the traditional chemical and pharma base.
- Edlon riding the semiconductor wave: Edlon has grown from about $10–12 million two years ago to about $25 million today, with further significant growth expected from semiconductor investments in the Americas and now starting in Europe.
- Mixing business consolidated for scale: A new head of Mixing has been appointed; designs and brands across Mixel, MixPro, and IMSD are being consolidated with a new go-to-market strategy, targeting $100 million in revenue in the next 3–4 years.
Tarak Patel: "Glass-lined business was nearly accounting for 80%- 90% of our business not so long ago, today, it's down to 50%, And also, chemicals and pharma were counting for nearly 80%, 90% of our overall business, that's also down to maybe 50%, So, as a Company and management, we've been very clear from day one that we need to diversify both the product portfolio and the industries that we serve because having all your eggs in one basket, catering to only one or two industries is going to be kind of detrimental and very risky if those markets going to slow down."
Margins & Costs
- International margins improved, India stable: Profitability margins improved in the international business, while margins in India have been stable for the last few quarters, the result of ongoing cost control measures and a focus on operational excellence.
- International margins to hold steady: Management expects the international business to trade around the same kind of margins for FY25; China's slow order intake will create some absorption issues, offset by European restructuring benefits.
- European restructuring underway: The UK site has been restructured to become a reglassing facility with a reduced cost structure, and a low-cost sourcing initiative in Eastern Europe has begun, with a few orders already placed to a local supplier.
- Gross margin expansion is temporary: Material consumption improved as a percentage because the top line degrew quarter-on-quarter (product side declined, services were more stable); management flagged this as "exceptionally better raw material consumption" that will revert once the mix normalizes.
- One-time costs hit Q4: A $1 million charge from Mixel PPA revaluation amortization and another $1 million in acquisition expenses (work on a couple of targets) weighed on the quarter.
- Using the down cycle for efficiency: Management is using the slow period to improve internal cost efficiency measures; as the market recovers, the benefits from today's work will translate into much better margins.
Balance Sheet & Cash Flow
- Debt repayment accelerated: Rs. 145 crores of long-term debt was repaid in FY24, and the entire debt from the Hyderabad and Vatva acquisitions taken in the past 2–3 years has been prepaid and closed.
- Working capital normalized in H2: Significantly improved cash generation in H2 came primarily from inventory optimization and cash collection focus; working capital had expanded in H1 for operational reasons but was brought back to decent levels.
- CRISIL upgrade: CRISIL upgraded the company's ratings to positive, reflecting the improved balance-sheet profile.
- Debt repayment to continue: Management plans to continue the debt repayment journey in upcoming years.
Strategic Initiatives & New Capabilities
- Two mixing patents granted: Two patents in the Mixing space have been issued in the name of GMM Pfaudler, strengthening the IP portfolio.
- Altilium partnership for process technology: The company is working with an engineering firm, Altilium, to combine equipment with process technology for a combined customer offer, extending market outreach.
- New US joint venture facility: A 51% shareholding was acquired in a facility in Georgia, southern US, specializing in reglassing and service stations; inauguration is set for July.
- Service center network expanding: New service centers have been added in Mavag, Switzerland, as well as in Brazil, America, and Italy.
- Service and reglass underpenetrated in India: India currently derives less than 10% of revenue from reglass and services, versus 30–40% in mature markets; management expects this component to increase in the next few years.
- Board strengthened: Ms. Shilpa Nirula was appointed as an Independent Director, effective May 22, 2024; with this appointment, 70% of the board now comprises independent directors.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Old guidance recalibration | Rs. 3,700 crores revenue and Rs. 630 crores EBITDA guidance will be recalibrated; Rs. 630 crores EBITDA called "a tough call" for FY25 | New guidance in "next few quarters" |
| Three-year strategic plan | Management will present a recalibrated three-year outlook to the external community | Investor Day in "a couple of months" |
| Mixing revenue target | Achieve $100 million in Mixing revenue | Next 3–4 years |
| Market turnaround | Full market turnaround expected; signs are positive but not out of the woods yet | Six to nine months |
| Chemical/agrochemical recovery | Overstocking problem to reduce; significant change expected | About nine months |
| Revenue and profitability growth | Conservative view of some growth in both revenue and profitability next year; could outperform if market improves quickly | FY25 |
| International margins | Expected to trade around current levels | FY25 |
| Debt repayment | Continue the debt repayment journey | Upcoming years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue | ₹741 cr, +8% YoY for the full year |
| EBITDA | ₹91 cr, margin at 12.3% |
| EBITDA margin (full year) | 13.8% |
| Profit after tax growth (full year) | +11% YoY |
| Order intake | ₹861 cr, +14% QoQ |
| Indian Glass-line order intake | ₹150–160 cr, doubled from ₹70–90 cr in Q1/Q2 |
| Large order received (US) | $12 mn |
| Backlog | ₹1,700 cr |
| Free cash flow (full year) | ₹253 cr, over 50% of EBITDA of ₹477 cr |
| Long-term debt repaid (full year) | ₹145 cr, comprising ₹96 cr India and ₹50 cr international |
| Net debt-to-equity | 0.4x |
| Net debt-to-EBITDA | 0.8x |
| Effective tax rate | 27% |
| Glass-line capacity utilization | ~65%; other product lines at 70–75% |
| Glass-line share of revenue | ~50%, down from 80–90% |
| Mixing revenue | ~$45 mn (nearly 13% of revenue) |
| Edlon revenue | $25–30 mn, up from $10–12 mn two years ago |
| One-time acquisition expense charge | $1 mn |
| One-time Mixel intangible amortization | $1 mn |